Newstral
Article
The Spokesman-Review on 2015-11-22 09:00
The Motley Fool: Spotlight on drugmaker Biogen - Sun, 22 Nov 2015 PST
Related news
- Motley Fool: Senior real estate - Sun, 11 Mar 2018 PSTThe Spokesman-Review
- The Motley Fool Takefortmyers.floridaweekly.com
- Motley Fool: A fat dividend to consider - Sun, 09 Aug 2020 PSTThe Spokesman-Review
- The Motley Fool: AT&T stock offers solid income - Sun, 12 Feb 2017 PSTThe Spokesman-Review
- Motley Fool: Clorox shares just keep getting shinier - Sun, 24 Apr 2016 PSTThe Spokesman-Review
- Motley Fool: A pipeline of potential profits - Sun, 30 Jul 2017 PSTThe Spokesman-Review
- Motley Fool: A biotech bargain? - Sun, 08 Apr 2018 PSTThe Spokesman-Review
- Motley Fool: Building material profits - Sun, 28 Oct 2018 PSTThe Spokesman-Review
- Motley Fool: A healthy opportunity - Sun, 11 Aug 2019 PSTThe Spokesman-Review
- Motley Fool: Dividends and growth - Sun, 21 Apr 2019 PSTThe Spokesman-Review
- Motley Fool: On Target - Sun, 12 Dec 2021 PSTThe Spokesman-Review
- Motley Fool :Banking toward profits - Sun, 06 Dec 2020 PSTThe Spokesman-Review
- Motley Fool: General dividends, growth - Sun, 19 May 2019 PSTThe Spokesman-Review
- The Motley Fool: Useful tips on investingseattletimes.com
- Motley Fool: A champion yield - Sun, 12 May 2019 PSTThe Spokesman-Review
- Motley Fool: A Shopify Spree - Sun, 07 Jul 2019 PSTThe Spokesman-Review
- Motley Fool: Banking on it - Sun, 04 Oct 2020 PSTThe Spokesman-Review
- Motley Fool: Gamble on Procter - Sun, 04 Nov 2018 PSTThe Spokesman-Review